Search Results for: lexaria

Lexaria Bioscience (LEXX.Q) announced today that its DehydraTECH™ technology has been embraced by consumer brands and is now available for sale in over 7,000 stores across the US. “Lexaria’s…
Lexaria Bioscience (LEXX.Q) announced today that dosing has been completed for its HYPER-H21-2 study, the Company’s second human clinical study of 2021.   Hypertension, also known as high blood…
Lexaria Bioscience (LEXX.Q) announced today that its tolerability and pharmacokinetic study VIRAL-A20-3 has been completed with positive results. Read full article here: https://equity.guru/2021/07/lexaria-bioscience-lexx-q-announces-positive-results-for-viral-a20-3-study-shares-climb-66/…
Lexaria Bioscience (LEXX.Q) announced today that its tolerability and pharmacokinetic study VIRAL-A20-3 has been completed with positive results.     The VIRAL-A20-3 study was performed using Sprague-Dawley rats, with…
Lexaria Bioscience (LEXX.Q) today announced results from its antiviral drug molecular characterization study VIRAL-MC21-1 recently completed by Canada’s premier federally funded research organization, the National Research Council (NRC).  …
Lexaria Bioscience (LLX.C) announced today that treatment and dosing in its human clinical study, HYPER-H21-1, have been completed ahead of schedule. Read full article here: https://equity.guru/2021/06/07/lexaria-bioscience-lxx-c-releases-progress-report-for-first-human-clinical-study/…
Lexaria Bioscience (LLX.C) announced today that treatment and dosing in its human clinical study, HYPER-H21-1, have been completed ahead of schedule.   “Completing this work in the midst of…
Lexaria Bioscience (LXX.C) has received test results for two new DehydraTECH 2.0 cannabidiol (CBD) formulations in its second 2021 applied research and development study program, HYPER-A21-2. Read full article…
Lexaria Bioscience (LXX.C) has received test results for two new DehydraTECH 2.0 cannabidiol (CBD) formulations in its second 2021 applied research and development study program, HYPER-A21-2. “One of our…
Lexaria Bioscience (LXX.C) has provided positive results from its extended stability testing, which has reported unparalleled stability for bottled cannabidiol (CBD)-containing beverages prepared using its technology. “I love reminding…